MET Gene Amplification by FISH

Casandra

Casandra Test Code AR35430Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 3001313CPT Code 88366

MET Gene Amplification by FISH

Also known as: MET_FISH

Clinical Use

Order Test

Use

This test aids in prognostication and therapeutic decisions for neoplasms where MET gene amplification has been demonstrated. It is a screening test used to identify MET gene amplification, which may be relevant in various tumor types, including non-small cell lung carcinoma. High-level MET amplification is considered an emerging biomarker for therapy with crizotinib, as defined by the National Comprehensive Cancer Network guidelines.

Special Instructions

Include surgical pathology report with the specimen. If multiple specimens are sent, a pathologist fee may be applied for block selection, unless specified otherwise. Clarification is required if multiple specimens are not accompanied with specific instructions for testing.

Limitations

This assay is not approved as a predictive biomarker for the therapeutic agent Emrelis; a different test, the Ventana SP44 immunostain, is required. The MET gene amplification is defined by a MET/CEP7 ratio of 2.0 or greater or an average MET gene copy number per cell of 6.0 or greater. It has not been cleared or approved by the US Food and Drug Administration. The test is performed in a CLIA-certified laboratory.

Test Details

New York Approved